Skip to Content
Merck

The Use of Lactose as an Alternative Coating for Nanoparticles.

Journal of pharmaceutical sciences (2020-02-01)
Jamie L Betker, Thomas J Anchordoquy
ABSTRACT

Nanoparticle-mediated drug delivery has long utilized PEGylation as a mechanism for reducing uptake by the reticuloendothelial system and extending circulation lifetimes. However, studies over the past 2 decades have established that immune responses to PEG can promote clearance on repeat injection and elicit life-threatening anaphylactic reactions in some patients. As a potential alternative to PEGylation, we explored the ability of utilizing lactose, a naturally occurring sugar that is common on the surface of blood cells, as a coating for lipoplexes. Our data indicate that lactose imparts similar effects as PEG in terms of reducing leukocyte uptake, extending circulation half-life, and enhancing delivery to the tumor and other organs. In addition, measurements of blood cytokine levels after repeat injection indicate that reduced levels of inflammatory cytokines (IL-6, IFN-γ, TNFα) are elicited in response to lipoplexes coated with lactose as compared to PEG. These data indicate that a lactose coating on lipoplexes results in slightly improved tumor accumulation as compared to PEGylated formulations while eliciting a reduced innate immune response.

MATERIALS
Product Number
Brand
Product Description

Avanti
Cholesterol (ovine), Avanti Polar Lipids
Avanti
20:0 PC, 1,2-diarachidoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
20:0 PC, 1,2-diarachidoyl-sn-glycero-3-phosphocholine, powder
Avanti
C16 Lactosyl(β) Ceramide (d18:1/16:0), Avanti Research - A Croda Brand 860576P, powder
Avanti
C16 PEG750 Ceramide, Avanti Research - A Croda Brand 880680P, powder